CellCyte Genetics Retains InCap Group to Advise on Business Strategy and inancing

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

finances

Bothell (euro adhoc) - CellCyte Genetics Retains InCap Group to
Advise on Business Strategy and Financing

BOTHELL, Wash., July 10 -- CellCyte Genetics Corporation (CellCyte)
(OTC Bulletin Board: CCYG) has engaged InCap Group, Inc. (InCap) to
provide strategic investment and financial advice and services.
CellCyte seeks to build shareholder value by monetizing its two core
platform technologies and will work with InCap to initiate a
corporate partnering strategy to exploit development and
commercialization of CellCyte's cell expander and stem cell delivery
technologies. "We are committed to realizing the value in our two
stem cell enabling technologies and look forward to the counsel InCap
can provide in this regard as well as their assistance in executing
staged capital raises," said Gary A. Reys, President and CEO of
CellCyte. "The promise of stem cells in regenerative medicine has
been hampered by the inability to generate sufficient cells and the
lack of effective non-invasive ways to deliver them to the
therapeutic target. CellCyte's two technology platforms may provide
the solutions to both of these fundamental problems. We are excited
about helping the Company commercialize its highly leveraged
technologies," noted Paul J. Marangos, Ph.D., a consultant with
InCap.

CellCyte's strategic initiatives include:

-- Transitioning from a research to a commercialization business approach
-- Establishing a partnering strategy targeting multiple companies
involved in the clinical exploitation of stem cells
-- Accelerating the development and commercialization of the company's
cell expander bioreactor technology
-- Staged milestone driven capital formation

About InCap Group
InCap Group, Inc., is an investment banking firm focused on the investment

management and securities brokerage industries. They provide merger
and acquisition services, capital raising services, valuations and
strategic advice to their clients. The value of their services is
derived from the market experience of their professionals. The
professionals at InCap were deeply involved in many of Legg Mason,
Inc.'s investment management acquisitions, which resulted in the firm
being transformed from a modest regional securities brokerage firm to
one of the ten largest asset management firms in the world. InCap's
professionals have worked at other leading industry firms including
Fidelity Investments, SEI Investments, PaineWebber, and Oppenheimer &
Co. For more information, please visit http://www.incapgroup.com.

About CellCyte Genetics CellCyte Genetics is a biotechnology
company engaged in the discovery, development and commercialization
of stem cell enabling therapeutic products. CellCyte is developing
products to allow more efficient delivery and increased retention of
adult stem cells to diseased organs, such as the heart. The goal of
these therapies is to increase the number of stem cells delivered to
a damaged organ, thereby markedly increasing organ healing and
functional restoration. The Company's lead product, CCG-TH30, is
being developed to send autologous bone marrow-derived (adult) stem
cells to the heart of patients after a heart attack.

For further information see: http://www.cellcyte.com.
Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS

DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933,
AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE
NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY
STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS
REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED
HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN
FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND
UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY
FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR
IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS,
INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT
INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR
"EXPECT" OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS
AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO,
THE RISKS ASSOCIATED WITH THE RESEARCH AND DEVELOPMENT OF
CCG-TH30PRIVATE PLACEMENT OFFERING(S) AND OTHER SERVICES PROVIDED TO
CELLCYTE BY INCAP. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE
REGULATORY APPROVAL PROCESS, COMPETITIVE PRODUCTS AND COMPANIES AND
THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND
DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S
DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY
ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE
AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO
OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE
REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE
FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE
BELIEFS, PLANS, EXPECTATIONS, AND INTENTIONS CONTAINED IN THIS NEWS
RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS,
PLANS, EXPECTATIONS, OR INTENTIONS WILL PROVE TO BE ACCURATE.
INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND
SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S
PERIODIC REPORTS FILED FROM TIME TO TIME WITH THE UNITED STATES
SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE COMPANY'S MOST
RECENT REPORTS ON FORM 10-KSB AND FORM 10-Q. THIS NEWS RELEASE HAS
BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKE FULL
RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE
OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS
RELEASE.

SOURCE CellCyte Genetics Corporation -0-
07/09/2008 /CONTACT: Investor Relations of CellCyte Genetics
Corporation, North America, +1-877-688-5050,
Investorrelations@cellcyte.com/

/Web site: http://www.cellcyte.com
http://www.incapgroup.com /
(CCYG CCYG.OB)

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: CellCyte Genetics Corporation
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

CONTACT: Investor Relations of CellCyte Genetics Corporation, North

America, +1-877-688-5050, Investorrelations@cellcyte.com

Branche: Biotechnology
ISIN: US15116P1030
WKN: A0MLCV
Börsen: Börse Frankfurt / Open Market
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse München / free trade